Aethlon Medical Inc.

Aethlon Medical Inc. creates affinity biofiltration devices to treat life-threatening diseases. The company's lead therapeutic candidate is the Aethlon Hemopurifier, a first-in-class device that targets the rapid elimination of infectious viruses and cancer-promoting exosomes from the circulatory system of treated individuals.

Expert Comments:

Management Q&A: View From the Top
James Joyce
Aethlon Medical Inc. has pioneered a novel biofiltration platform that was used effectively against Ebola in 2014. Now this broad-spectrum platform is being tested against cancer and other life-threatening diseases. Aethlon CEO James "Jim" Joyce describes how this device is helping transform modern healthcare.
read more >
"Aethlon Medical Inc.'s lead therapeutic, the Hemopurifier, is a first-in-class device that selectively and rapidly eliminates circulating viruses and tumor-secreted exosomes that promote cancer progression. The Hemopurifier was named one of the top 25 inventions of 2014 by Time magazine, and one of the 11 most remarkable advances in healthcare in 2014. That's a really impressive accomplishment. We've seen a lot of acceleration for Aethlon Medical during the past year, since the Hemopurifier was used successfully to treat an Ebola patient in Germany. It reduced the viral load by 99% in less than seven hours, which piqued interest in the company. Since then, Aethlon has been investigating potential applications of its Hemopurifier to a broad spectrum of the world's deadliest viral pathogens, including dengue fever, Ebola and strains of avian influenza. . ." read more >

Kayt Sukel, Fortune (9/10/15)
"Current trends also have companies looking at the use of sensors, robotics and analytics to better understand the nature of infectious disease; one example. . .is Aethlon Medical Inc.'s Hemopurifier, a bio-filtration device that captures viruses and toxic proteins in the blood. . .Hemopurifier can be used for the treatment of Ebola, as well as for HIV, hepatitis C and other illnesses. TIME Magazine named the device one of the best inventions of 2014." Read the full story here.

"Aethlon Medical Inc. uplisted to the NASDAQ in mid-July. . .the company uses dialysis-like affinity and filtration platforms to remove cancer-causing agents from the circulatory system. Aethlon has approved products that remove viruses, and is now also targeting breast cancer." read more >

"Aethlon Medical Inc. has a product called Hemopurifier, an extracorporeal blood filter used with typical blood circulatory equipment, such as dialysis machines. Initially the company developed the device to remove the hepatitis C virus (HCV) from the blood, and it has shown some success in that regard. In fact, a small, U.S.-based clinical study with HCV patients recently started. But it may have more utility than in just HCV. In fact, Hemopurifier was used with an Ebola patient who became infected during the recent outbreak in West Africa. . .prior to Hemopurifier administration, the patient had multiple organ failure, was unconscious and had a viral load of 400,000 (400K) virus copies/ml. Following a 6.5-hour treatment with Hemopurifier viral load was 1K virus copies/ml. Hemopurifier captured 253 million copies of Ebola. . .the fact that it captured a significant amount of the virus certainly seems encouraging. Aethlon is now seeking Humanitarian Device Exemption from the FDA, which would allow use of Hemopurifier for Ebola in emergency situations. The company is also considering initiation of Ebola studies in both the U.S. and Canada. . ." read more >

Amit Tandon, SeeThruEquity (7/8/15)
"Aethlon Medical Inc. announced that its shares would be uplisting to the NASDAQ Capital Market. Clearly the move to NASDAQ represents a significant accomplishment for the company, which has been striving for this goal for some time. We expect the transition to have a positive effect on Aethlon's liquidity, improve the company's visibility and also open it up to new potential mutual funds, pensions and other institutional investors who may have been restricted from investing in the company while it traded on the OTC Marketplace."

Amit Tandon, SeeThruEquity (2/13/15)
"Aethlon Medical Inc. has increased its net worth by approximately $16M since the end of FY/14, with no notes in default and positive shareholders' equity and working capital as of December 31, 2014. . .the company announced the launch of an FDA approved clinical study testing the Aethlon Hemopurifier. . .this announcement comes on the heels of the earlier announcement that the FDA had approved the testing in Ebola patients of Aethlon's Hemopurifier device."

More Expert Comments

Experts Following This Company

Jay Albany, Healthcare Analyst – SeeThruEquity
Caroline Corner, Managing Director, Equity Research – Cantor Fitzgerald
Brian Marckx, CFA – Zacks Small-Cap Research
Ajay Tandon, CEO – SeeThruEquity
Amit Tandon, Director of Research – SeeThruEquity

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.